PB 22 of 2014
National Health (Listed drugs on F1 or F2) Amendment Determination 2014 (No. 2)
National Health Act 1953
I, ADRIANA PLATONA, Assistant Secretary, Pharmaceutical Evaluation Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this determination under subsection 85AB(1) of the National Health Act 1953.
Dated 24 March 2014
ADRIANA PLATONA
Assistant Secretary
Pharmaceutical Evaluation Branch
Pharmaceutical Benefits Division
Department of Health
Part 1 Preliminary
1 Name of Determination
(1) This Determination is the National Health (Listed drugs on F1 or F2) Amendment Determination 2014 (No. 2).
(2) This Determination may also be cited as PB 22 of 2014.
2 Commencement
This Determination commences on 1 April 2014.
3 Amendment of National Health (Listed drugs on F1 or F2) Determination 2010
Schedule 1 amends the National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010).
Schedule 1 Amendments
(Section 3)
[1] Schedule 1, after item dealing with Acetazolamide
Omit
Acitretin
[2] Schedule 1, after item dealing with Cladribine
Insert
Clobetasol
[3] Schedule 1, after item dealing with Disopyramide
Insert
Dolutegravir
[4] Schedule 1, after item dealing with Doxepin
Omit
Doxorubicin, peglyated liposomal
[5] Schedule 1, after item dealing with Glycomacropeptide and essential amino acids with vitamins and minerals
Insert
Glycopyrronium
[6] Schedule 1, after item dealing with Methysergide
Omit
Metoclopramide
[7] Schedule 1, after item dealing with Pancrelipase
Insert
Panitumumab
[8] Schedule 2, after item dealing with Aciclovir
Insert
Acitretin
[9] Schedule 2, after item dealing with Doxorubicin
Insert
Doxorubicin - Peglyated Liposomal
[10] Schedule 2, after item dealing with Methylprednisolone
Insert
Metoclopramide
